 |
|
|
|
|
I. Introduction |
|
|
|
| |
|
|
|
|
|
II. Defining the Landscape: General and Industry-Specific Trends Affecting the Drug Development Environment |
|
|
|
| |
|
|
|
|
|
A. The Effects from Without |
|
|
|
| |
|
|
|
|
|
B. The Effects from Within |
|
|
|
| |
|
|
|
|
|
III. Contracting Out Versus Contracting in: From Vendor to Virtual Corporation |
|
|
|
| |
|
|
|
|
|
A. The Potential for a New Relationship Between Sponsor and CRO |
|
|
|
| |
|
|
|
|
|
B. The Advantages and the Pitfalls of Contracting In |
|
|
|
| |
|
|
|
|
|
IV. Whether and How to Contract in: The Decision-Making Process |
|
|
|
| |
|
|
|
|
|
A. Evaluating the Need for a CRO |
|
|
|
| |
|
|
|
|
|
B. Traditional Strategies for Contracting Out to a CRO |
|
|
|
| |
|
|
|
|
|
C. The Alternative of Contracting In |
|
|
|
| |
|
|
|
|
|
D. The Key Differences Between the Traditional View and the Alternative |
|
|
|
| |
|
|
|
|
|
E. Some Examples of CRO Studies |
|
|
|
| |
|
|
|
|
|
V. Choosing to Contract in: Strategies for Successful CRO Selection |
|
|
|
| |